Muna Alemi Yahya
Shilhav Meisel Sharon
Shay Hantisteanu2
Ilan Bruchim- 1Gynecologic Oncology Division, Department of Obstetrics and Gynecology, Hillel Yaffe Medical Center, Hadera, Israel
- 2Gynecology Laboratory, Department of Obstetrics and Gynecology, Hillel Yaffe Medical Center (Affiliated with the Technion Israel Institute of Technology), Hadera, Israel
- 3Department of Human Molecular Genetics and Biochemistry, Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel
Treatment of patients with gynecologic malignancies diagnosed at advanced stages remains a therapeutic challenge. Survival rates of these patients remain significantly low, despite surgery and chemotherapy. Advances in understanding the role of the immune system in the pathogenesis of cancer have led to the rapid evolution of immunotherapeutic approaches. Immunotherapeutic strategies, including targeting specific immune checkpoints, as well as dendritic cell (DC) immunotherapy are being investigated in several malignancies, including gynecological cancers. Another important approach in cancer therapy is to inhibit molecular pathways that are crucial for tumor growth and maintenance, such as the insulin-like growth factor-1 (IGF1) pathway. The IGF axis has been shown to play a significant role in carcinogenesis of several types of tissue, including ovarian cancer. Preclinical studies reported significant anti-proliferative activity of IGF1 receptor (IGF1R) inhibitors in gynecologic malignancies. However, recent clinical studies have shown variable response rates with advanced solid tumors. This study provides an overview on current immunotherapy strategies and on IGF-targeted therapy for gynecologic malignancies. We focus on the involvement of IGF1R signaling in DCs and present our preliminary results which imply that the IGF axis contributes to an immunosuppressive tumor microenvironment (TME). For the long term, we believe that restoring the TME function by IGF1R targeting in combination with immunotherapy can serve as a new clinical approach for gynecological cancers.
Introduction
Treatment of Gynecologic Malignancies: Current Advances
Endometrial cancer is the most common gynecological malignancy in the developed world and the second most common in developing countries (1, 2). Treatment includes surgery and adjuvant radiotherapy, and/or chemotherapy depending on surgical staging. Women with metastatic or recurrent disease have poor prognosis, with median survival of 7–12 months (3). Endometrial cancer has two histopathological subtypes. About 80% of endometrial cancers are Type I, which has several mutations, including microsatellite instability (MSI), KRAS, PTEN, PIK3CA, and β-catenin. Type II, usually aneuploidy with poorer prognosis, contains alterations in p53, HER2/neu, p16, E-cadherin CDKN2A, and/or ERBB2 genes. Patients with mismatch repair-deficient (dMMR) or MSI tumors who have progressed on platinum-based chemotherapy might be particularly sensitive to immune checkpoint inhibitors, such as pembrolizumab, a humanized antibody that targets the PD-1 receptor (described in more detail in Section Author’s Perspective). In addition, the mTOR inhibitors everolimus and temsirolimus demonstrated antitumor activity in endometrial cancer, with greatest sensitivity in cells with PIK3CA or PTEN mutations (4, 5). Another important agent is bevacizumab, a monoclonal antibody against vascular endothelial growth factor (VEGF), which was shown to be effective in endometrial cancer (6). Other targeted therapies against somatic mutation in endometrial cancer, including PI3K and MEK, are under investigation (7–9).
Cervical cancer is the third most common cause of death from gynecological malignancies in the United States (1). The pathology behind cervical cancer is related to human papilloma virus (HPV) infection, especially genotypes 16 and 18. This finding led to the development of vaccines to prevent HPV infection. Despite the known etiology and the PAP screening test, advanced cervical cancer is a common diagnosis. The standard treatment of advanced cervical cancer is based on chemotherapy; however, poor survival rates have led to new therapeutic approaches. Recent Phase 3 studies found that adding bevacizumab to standard chemotherapy improved overall survival and progression-free survival in women with advanced, metastatic, or recurrent cervical cancer (10). Other immunotherapeutic models aimed at targeting the E6 and E7 oncoproteins of HPV will be discussed in Section “Author’s Perspective.”
Ovarian cancer is the second most common cancer and the leading cause of death from gynecological malignancy in the United States (2, 11). Epithelial ovarian cancer (EOC) represents approximately 90% of ovarian cancers. Conventional treatment includes surgical cytoreduction and adjuvant chemotherapy, which may lead to recovery in early stages. Unfortunately, there are no efficient screening tests to enable early diagnosis; hence, the vast majority of patients are diagnosed at an advanced stage and 80% of these patients will have recurrence and ultimately die of the disease (12–14). Consequently, intensive research has been undertaken to investigate alternative therapies for this disease. Angiogenesis plays a fundamental role in the pathogenesis of EOC; therefore, bevacizumab is used as an adjuvant therapy, as it prolongs progression free survival and may improve overall survival in high-risk patients (15–18). Additional agents are the poly ADP-ribose polymerase (PARP) inhibitors, which inhibit the PARP protein that functions in single strand DNA repair, leading to apoptosis. The PARP inhibitors are most effective in cancers with a BRCA mutation, because BRCA protein is involved in double-stranded DNA repair (19). Olaparib, a PARP inhibitor agent, is currently approved in the USA and Europe for patients with recurrent, platinum-sensitive, BRCA-mutation ovarian cancer (11, 20). Nowadays, precision medicine is getting more attention in the field of gynecology-oncology. Barroilhet and Matulonis provides an updated overview regarding this concept which is based on tumor gene sequencing, in order to match agents targeted against specific tumor mutations regardless of the involved organ (21).
Immunotherapeutic Approaches for Gynecological Cancers
The immune system is composed of humoral and cellular immune responses. Cell-mediated immunity is important for eliminating cells infected with pathogen and tumor cells; the dendritic cells (DCs) are professional antigen-presenting cells (APCs) that express pattern recognition receptors. These receptors together with cytokines and chemokines cause peripheral immature DCs to mature and migrate to lymphoid tissue, where they interact with lymphocytes (22–25). The humoral response is mediated by antibodies against pathogens. As antigens enter the body, B cells respond by undergoing activation, proliferation, and differentiation to release antibodies (26). The formation of antigen-specific antibodies requires B and T lymphocytes, as well as APCs. Based on the immuno-editing concept (27), the immune system eradicates new emerging tumor cells; however, in some cases one cell remains dormant, escapes the immune system, and proliferates leading to disequilibrium between the immune system and cancerous cells. Immune-inflammatory cells, among others, comprise the tumor microenvironment (TME). Considering the widely established link between inflammation and cancer, the TME has a significant role in tumorigenesis (28–31). Consequently, immunotherapeutic approaches against cancer have recently emerged.
The main immunotherapeutic approaches are DC vaccines and blockade of immune checkpoints, including programmed cell death, PD-1/PD-L1. PD-1 is an immunoinhibitory receptor that is expressed on T cells, B cells, monocytes, natural killer cells, and many tumor-infiltrating lymphocytes. Interaction of the receptor with its ligand, the PD-L1, which was found to be expressed in some cancer cells, restrains the immune system from attacking cells in the body (32, 33). The immune system’s involvement in endometrial cancer is not fully understood; the FDA approved pembrolizumab (anti PD-1 antibody) for patients with MSI or MMR deficiency who did not respond to prior therapies (34).
Cervical cancer is related to chronic HPV infection in 99.7% of cases. The HPV integrates into the cellular genome and expresses two oncoproteins, E6 and E7. The E6 oncoprotein inhibits p53; thus, leading to proliferation, while E7 prevents apoptosis (35). Immunotherapeutic approaches which target the E6 and E7 oncoproteins are under investigation. Therapeutic vaccines which include vaccinia- and listeria-based vaccines and DC vaccines have shown promising results (35, 36). Specifically, DC vaccines, which are based on autologous DCs transfected with E6 or E7 RNA in order to stimulate cytotoxic T cell response, led to effective eradication of cervical cancer cells (37). Unfortunately, small clinical trials demonstrated T cell response without a clinical benefit (38, 39). The immunoinhibitory ligand, PD-L1 was observed in 95% of cervical intraepithelial neoplasia and in 80% of cervical squamous cell carcinoma, but was not detected in normal cervical epithelial cells implying a potential therapeutic benefit (40). In the KEYNOTE-028 trial, pembrolizumab has shown preliminary promise as second-line therapy for cervical cancer (41). Finally, CAR-T cells are genetically modified T cell that are taken from tumor tissue, expanded ex vivo and transferred back into the patient. A small trial on nine patients with recurrent metastatic cervical cancer showed a complete response in one patient and partial response in two others (42).
Despite significant advances in surgery and chemotherapy treatments, ovarian cancer is still the most lethal of all gynecological malignancies. Data suggest that the presence of tumor-infiltrating lymphocytes at diagnosis, improves survival rates (43, 44). This reflects the crucial role of the immune system in eliminating tumor cells. Of interest, early reports showed significant efficacy for the CAR-T strategy (45). Treatments targeting the immune checkpoints PD-1/PD-L1 and the inhibitory receptors of cytotoxic T lymphocyte-associated antigen 4 were approved for use in melanoma and have been evaluated for treatment of EOC (46–48). The anti-PD-1 agent nivolumab, and the anti PD-L1 agents avelumab and pemrolizumab, are being evaluated in clinical trials with promising results (48–50). Various vaccine models, including simple vaccine preparations consisting of proteins expressed in EOC and more complex models, such as DC vaccines have been developed. In the latter model, DCs are matured outside the body and programmed to detect and attack tumor cells upon reinjection into the patient (51).
The Insulin-Like Growth Factor (IGF) Axis in Gynecological Cancer
The IGF system has a pivotal role in cell proliferation, differentiation, and apoptosis (52). This system is composed of ligands (IGF-1, IGF-2), IGF receptors (IGF1R, IGF2R), and six IGF binding proteins (IGFBPs 1–6). The biologic effects of the ligands are mediated by the IGF1R, which undergoes autophosphorylation of its tyrosine kinase domain, with ensuing phosphorylation of insulin receptor (INSR) substrates. Consequently, the ras–raf–MAP kinase and the PI3K–PDK1–Akt/PKB signaling pathways are activated, resulting in metabolic actions, proliferation, and reduction in apoptosis (53). Unlike the IGF1R, the IGF2R, which is apparently not involved in IGF signaling, is mainly responsible for targeting the highly mitogenic IGF2 for lysosomal degradation (54). Worthy of mention, the IGF1R shares a high degree of homology with the INSR, leading to a certain level of cross talk between insulin, IGFs, and their receptors. The complexity of these interactions was widely discussed and studied by several studies (55–58). The interplay between the IGF signaling and estrogen pathways is of importance as well (59), and relevant to us is the well-established cross talk between these pathways in endometrial cancer (60, 61). In addition to its normal physiological roles, the IGF axis and in particular, the IGF1R are also involved in carcinogenesis. Epidemiologic observations showed an association between circulating IGF-1 levels and prostate, premenopausal breast and colorectal cancer incidence (62). Consequently, the IGF axis became an attractive therapeutic target.
Targeting IGF1R with specific monoclonal antibodies inhibited IGF-induced proliferation in both Type I and II endometrial cancer (63, 64). Moreover, a human monoclonal IGF1R antibody inhibited endometrial cancer proliferation in clinical trials (65). In cervical cancer animal models, treatment with IGF1R antibodies inhibited tumor growth and caused tumor regression (66). In addition to monoclonal antibodies, small molecule IGF1R inhibitors such as NVP-AEW541 had anti-proliferative effects on ovarian cancer cells (67). Current ovarian cancer clinical trials are evaluating IGF inhibitors alone, or in combination with biologic agents or chemotherapy.
These findings and others have turned the IGF1R into a promising target for treating cancer; yet there is no clear-cut evidence to approve its use as a single agent.
Author’s Perspective
The complexity of the IGF1R signaling pathway was suggested as one cause of the failure of IGF-targeting strategies (68). Parallel growth and survival pathways, as well as a lack of proper biomarkers for patient selection are additional possible explanations. Given the genetic complexity of most tumors, including gynecological cancers, accumulating evidence suggests that combination strategies of targeting multiple signaling pathways will probably be required to obtain therapeutic effects. Shao et al. showed that dual anti-VEGF and anti-IGF1R treatment (bevacizumab and cixutumumab, respectively) enhanced tumor growth inhibition in ovarian cancer cells and provided significant benefit over either treatment alone (69). Another study reported that the IGFIR kinase inhibitor BMS-536924 increased the cytotoxicity induced by the PARP inhibitor 3-aminobenzamide in human EOC cell lines, suggesting a combination of IGF1R inhibitor and a PARP inhibitor to decrease resistance to treatment (70). Haluska et al. demonstrated functional cross talk between the IGF and HER family of receptors in ovarian cancer cells (71). In line with the development of immunotherapeutic approaches in various cancer types, targeting the IGF1R signaling pathway in combination with immunotherapy should be investigated. This is supported by the finding that PI3K–AKT pathway inhibitors sensitize tumor cells to immunotherapy (72). It seems that a deep understanding of the involvement of the IGF pathway in host immunity and in immune cells in the TME constitutes a basis for the combination targeting strategy described above. Interestingly, a recent published review describes a similar approach regarding the estrogen pathway involvement in TME (73). In the context of combined therapies estrogen is highly relevant, considering the interplay between estrogen and IGF1. The role of IGF1R in the development and function of the immune system appears to be complex and variable; nonetheless, there is compelling evidence that within a TME, the IGF axis promotes an immunosuppressive, anti-inflammatory response that enables cancer growth. For example, IGF1 was shown to negatively regulate DC activation; thereby impairing the antigen-presentation function (74). IGF1 was also shown to stimulate the proliferation of Treg cells, which are known to suppress local T cell immune responses (75). Moreover, IGF1R activation was linked to macrophage polarization from the pro-inflammatory M1 to the pro-tumorigenic M2 phenotype in various animal models (76). A recent study showed that IGF1 production by myeloid-derived suppressor cells promoted stromal cell migration and tumor invasion, implying that IGF1 might also play a role in the tumor-promoting effect of myeloid-derived suppressor cells (77). Taken together, the interplay between the IGF1 axis and immune cells should be investigated further. This will contribute to future studies involving IGF1R targeting in combination with immunotherapy for gynecologic malignancies.
IGF1R Monoclonal Antibodies and Tyrosine Kinase Inhibitor (TKI) Inhibit the IGF1-Induced Activation of Intracellular Cascades
We have been investigating the effect of IGF1R targeting in endometrial and ovarian cancer for several years. IGF1R-targeting with monoclonal antibodies and specific IGF1R TKIs inhibited IGF-induced proliferation in both Type I and II endometrial carcinomas (63, 64). In addition to the eliminated IGF1-stimulated proliferation, IGF1R inhibitors increased apoptosis. Cixutumumab, a fully human monoclonal antibody against IGF1R, inhibited IGF1-mediated biological actions and cell signaling events in four endometrial carcinoma-derived cell lines. Cixutumumab blocked the IGF1-induced autophosphorylation of IGF1R and reduced IGF1R expression. Recent studies demonstrated that MK-0646 had a potent anti-proliferative effect in Type I and II endometrial cancer cell lines, associated with a decrease in IGF1-induced IGF1R, AKT, and ERK1/2 phosphorylation. Interestingly, a different response to IGF1R blocking with MK-0646 was observed in Type I and Type II endometrial cancer. In addition, a previous study showed that IGF1R-targeted therapy has significant anti-neoplastic activity in ovarian cancer cells (67).
Tumor Suppressor p53 and BRCA1 Are Potential Biomarkers for IGF1R-Targeted Therapy
Following the failure of the IGF-targeting strategies, another possible approach is identifying predictive tumor biomarkers that will increase the efficacy of IGF1R-targeted therapy. These predictive biomarkers are intended for the process of developing early, innovative, patient screening methodologies that will predict the response to personalized therapy and resistance to IGF1R-targeted therapy. Several studies have provided evidence that the IGF1R gene transcription rate depends on a number of stimulatory nuclear proteins and is modulated by negative transcriptional regulators, including p53, p63, and p73 (78, 79) and the BRCA1 gene (80, 81). The IGF1R system is regulated by the p53 pathway in several malignancies, including endometrial cancer and ovarian cancer (82). Using USC-derived cell lines, Attias-Geva et al. demonstrated that p53 negatively regulates IGF1R gene expression via a mechanism that involves interaction with the zinc finger protein Sp1, a potent transactivator of the IGF1R gene (82). BRCA1 is a tumor suppressor whose mutation was correlated with the appearance of familial breast and/or ovarian cancer at young ages. Our group reported a high rate (25.8%) of the predominant BRCA1/2 mutations in unselected Jewish patients with USC (83). Moreover, immunohistochemical studies of USC tumors revealed high protein expression of BRCA1 and IGF1R in primary and metastatic tumors. Interestingly, we found that BRCA1 expression led to significantly reduced IGF1R promoter activity in USC cell lines. These results are consistent with the notion that loss of inhibitory control due to BRCA1 mutation may lead to enhanced IGF1R expression and eventually, increased proliferation (84). Taken together, our results suggest that BRCA1 mutational status may predict IGF1R inhibitor efficacy. This is supported by the recent study of Cohen-Sinai et al., which demonstrate a reduced inhibitory effect of anti-IGF1R treatment in mutant BRCA1-expressing cells (85).
Involvement of the IGF Axis in DCs
Although the involvement of the IGF axis and the IGF1R in ovarian cancer has been widely investigated, the exact function of IGF1R in host immunity and in tumor-infiltrating immune cells is still not clear. It has been shown that IGF1 is expressed in many immune cells and bone marrow stromal cells (86). In addition, nearly all immune cells such as T lymphocytes and B lymphocytes (87), mononuclear cells (88), and NK-cells (89) express IGF1R and are susceptible to the effects of IGF. A recent study showed that long-term IGF treatment resulted in delayed maturation of DCs and suppression of DC-mediated immunity. Specifically, treatment of DCs with the IGF1R inhibitor NVP-AEW541 restored DC-mediated antigen presentation and antitumor immunity (90). Moreover, it has been shown that IGFs enhance the secretion of IL-10 in bone marrow monocyte-derived DCs, thereby enhancing the immunosuppressive status of the tumor environment. Accordingly, blocking the IGF1 signaling pathway, apart from its effect on cancer cells, provides a new target to generate potent antitumor immunity by rescuing the impaired function of DCs. To examine IGF1R signaling activation in DCs, human leukemic HL-60 cells were differentiated to DCs using calcium ionophore (Figure 1A), treated with IGF1 and harvested, followed by western blot assay. Results show that DC differentiation was associated with a marked decrease in phosphorylated levels of IGF1R and in total IGF1R expression (Figure 1B). Of interest, undifferentiated HL-60 cells displayed high basal levels of phosphorylated IGF1R. Since undifferentiated HL-60 cells (control) exhibited basal phosphorylation of IGF1R, cells were treated with the IGF1R inhibitor prior to DC differentiation. To examine the effect of IGF1R inhibition on the IGF1 pathway in HL-60 cells, the cells were treated with IGF1R inhibitor (NVP-AEW541) for 1, 5, 24, and 48 h. As a result, IGF1R and AKT (downstream mediator) phosphorylation levels decreased (Figure 1C). Considering these results, it was then relevant to question whether blocking IGF1R in DCs would have a significant effect on ovarian carcinoma cells. DC differentiation was induced with or without NVP-AEW541 treatment. Differentiated cells were then co-cultured with EOC cells (ES2 and SKOV3) and a wound scratch assay was performed. As shown in Figure 2, results demonstrated decreased migration of ES2 and SKOV3 cells when co-cultured with DCs pre-treated with NVP-AEW541, as compared to untreated DCs. To note, an initial flow cytometry experiment implies that the NVP-AEW541 treatment accelerates the DCs maturation (not shown). Nonetheless, our findings are preliminary and should be furtherly studies.
Figure 1. Dendritic cell (DC) differentiation of HL-60 cells show reduced total and phosphorylated IGFIR protein levels. (A) Human leukemic HL-60 cells were differentiated to DCs by treatment with 0.5, 1, and 2.5 μg/ml of calcium ionophore (CI) for 72 h. (B) Human leukemic HL-60 cells were treated with 0.5, 1, and 2.5 g/ml of CI for 72 h and 10 min before harvest, cells were treated with insulin-like growth factor (IGF)1. Whole-cell lysates were resolved on SDS-PAGE and immunoblotted with the specified antibodies. Level of tubulin was used as a loading control. (C) Human leukemic HL-60 cells were treated with 2 μM of NVP-AEW541 for 1, 5, 24, and 48 h. Whole-cell lysates were resolved on SDS-PAGE and immunoblotted with the specified antibodies. Level of tubulin was used as a loading control.
Figure 2. NVP-AEW541 treated dendritic cells decrease ovarian cancer cell migration. Cell migration was detected by wound scratch assay. Representative wound closure images from three experiments are shown. Human leukemic HL-60 cells were treated with 1 μg/ml of CI and with 2 μM of NVP-AEW541 for 72 h after which they were co-cultured with the epithelial ovarian cancer (EOC) cells ES2 (A) and SKOV3 (B). Scratch was applied 24 h post cell merge. The growth of EOC cells into the scratch zone is demonstrated here at time 0, 24, and 48 h after scratch. The graphs represent average growth score of three independent experiments of ES2 and SKOV3 cells (*P < 0.05).
Summary and Conclusion
Collectively, recent evidence suggests that in addition to its direct role in tumor cell growth, the IGF axis contributes to the immunosuppressive TME leading to inhibition of the antitumoral T-cell-mediated responses. It is expected that immunotherapy will be potentiated when combined with IGF1R signaling blockade directed at inactive antigen-presenting DC or suppressive immune cells. Future studies evaluating the role of the IGF1 signaling pathway in tumor infiltrating immune cells in gynecologic malignancies will deepen our understanding of the feasibility of the combined therapy. Moreover, characterizing the TME and identifying new biomarkers will contribute to the development of precision gynecologic cancers treatments.
Author Contributions
MY and SS designed and performed the laboratory studies presented in the manuscript. MY and SS acquired and interpreted the data presented in the manuscript. MY and SS were involved in writing the drafts of the paper and the final version. SH was involved in the designing and performing the laboratory studies presented in the manuscript. He was involved in writing the drafts of the paper and the final version. MH was involved in the designing of the laboratory studies presented in the manuscript. He was involved in writing the drafts of the paper and the final version. IB designed the studies, acquired and interpreted the data presented in the manuscript. He was involved in writing the drafts of the paper and the final version. Also in submitting the manuscript.
Conflict of Interest Statement
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Supplementary Material
The Supplementary Material for this article can be found online at https://www.frontiersin.org/articles/10.3389/fendo.2018.00297/full#supplementary-material.
References
1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA Cancer J Clin (2018) 68:7–30. doi:10.3322/caac.21442
2. Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin (2015) 65:87. doi:10.3322/caac.21262
3. Oza AM, Elit L, Tsao MS, Kamel-Reid S, Biagi J, Provencher DM, et al. Phase II study of temsirolimus in women with recurrent or metastatic endometrial cancer: a trial of the NCIC Clinical Trials Group. J Clin Oncol (2011) 29:3278–85. doi:10.1200/JCO.2010.34.1578
4. Shoji K, Oda K, Kashiyama T, Ikeda Y, Nakagawa S, Sone K, et al. Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas. PLoS One (2012) 7(5): e37431. doi:10.1371/journal.pone.0037431
5. Weigelt B, Warne PH, Lambros M, Reis-Filho JS, Downward J. Genetic determinants of mTOR inhibitor response in breast and endometrial cancer. Proceedings of the 103rd Annual Meeting of the American Association for Cancer Research. Chicago, IL/Philadelphia: AACR (2012).
6. Aghajanian C, Sill MW, Darcy KM, Greer B, McMeekin DS, Rose PG, et al. Phase II trial of bevacizumab in recurrent or persistent endometrial cancer: a Gynecologic Oncology Group study. J Clin Oncol (2011) 29:2259–65. doi:10.1200/JCO.2010.32.6397
7. Depreeuw J, Hermans E, Schrauwen S, Annibali D, Coenegrachts L, Thomas D, et al. Characterization of patient-derived tumor xenograft models of endometrial cancer for preclinical evaluation of targeted therapies. Gynecol Oncol (2015) 139:118–26. doi:10.1016/j.ygyno.2015.07.104
8. Wang Y, Gao C, Zhang Y, Gao J, Teng F, Tian W, et al. Visfatin stimulates endometrial cancer cell proliferation via activation of PI3K/Akt and MAPK/ERK1/2 signalling pathways. Gynecol Oncol (2016) 143:168–78. doi:10.1016/j.ygyno.2016.07.109
9. Oda K, Ikeda Y, Kashiyama T, Miyasaka A, Inaba K, Fukuda T, et al. Characterization of TP53 and PI3K signaling pathways as molecular targets in gynecologic malignancies. J Obstet Gynaecol Res (2016) 42(7):757–62. doi:10.1111/jog.13018
10. Tewari KS, Sill MW, Long HJ, Penson RT, Huang H, Ramondetta LM, et al. Improved survival with bevacizumab in advanced cervical cancer. N Engl J Med (2014) 370:734. doi:10.1056/NEJMoa1309748
11. Jason GC, Khon EC, Ketchener HC, Ledermann JA. Ovarian cancer. Lancet (2014) 384:1376–88. doi:10.1016/S0140-6736(13)62146-7
12. Altekruse SF, Kosary CL, Krapcho M, Neyman N, Aminou R, Waldron W, et al. SEER Cancer Statistics Review. Bethesda, MD: National Cancer Institute (1975–2015).
13. Armstrong DK, Bundy B, Wenzel L, Huang HQ, Baergen R, Lele S, et al. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med (2006) 354:34–43. doi:10.1056/NEJMoa052985
14. Trimbos JB, Parmar M, Vergote I, Guthrie D, Bolis G, Colombo N, et al. International Collaborative Ovarian Neoplasm trial 1 and Adjuvant Chemo Therapy in Ovarian Neoplasm trial: two parallel randomized phase III trials of adjuvant chemotherapy in patients with early stage ovarian carcinoma. J Natl Cancer Inst (2003) 95:105–12. doi:10.1093/jnci/95.2.105
15. Aghajanian C, Goff B, Nycum LR, Wang YV, Husain A, Blank SV. Final overall survival and safety analysis of OCEANS, a phase 3 trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent ovarian cancer. Gynecol Oncol (2015) 139:10–6. doi:10.1016/j.ygyno.2015.08.004
16. Aghajanian C, Blank SV, Goff BA, Judson PL, Teneriello MG, Husain A, et al. OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer. J Clin Oncol (2012) 30:2039. doi:10.1200/JCO.2012.42.0505
17. Aghajanian C, Goff B, Nycum LR, Wang Y, Husain A, Blank S. Independent radiologic review: bevacizumab in combination with gemcitabine and carboplatin in recurrent ovarian cancer. Gynecol Oncol (2014) 133:105–10. doi:10.1016/j.ygyno.2014.02.003
18. Coleman RL, Brady MF, Herzog TJ, Sabbatini P, Armstrong DK, Walker JL, et al. A phase III randomized controlled clinical trial of carboplatin and paclitaxel alone or in combination with bevacizumab followed by bevacizumab and secondary cytoreductive surgery in platinum-sensitive, recurrent ovarian, peritoneal primary and fallopian tube cancer (Gynecologic Oncology Group 0213). Scientific Plenary #3 Presented at the 2015 Annual Meeting for Women’s Cancers. Chicago, IL (2015).
19. Konecny GE, Kristeleit RS. PARP inhibitors for BRCA1/2-mutated and sporadic ovarian cancer: current practice and future directions. Br J Cancer (2016) 115:1157–73. doi:10.1038/bjc.2016.311
20. Wiggans AJ, Cass GK, Bryant A, Lawrie TA, Morrison J. Poly(ADP-ribose) polymerase (PARP) inhibitors for the treatment of ovarian cancer. Cochrane Database Syst Rev (2015) 5:CD007929. doi:10.1002/14651858.CD007929.pub3
21. Barroilhet L, Matulonis U. The NCI-MATCH trial and precision medicine in gynecologic cancers. Gynecol Oncol (2018) 148(3):585–90. doi:10.1016/j.ygyno.2018.01.008
22. Vos Q, Lees A, Wu ZQ, Snapper CM, Mond JJ. B-cell activation by T-cell-independent type 2 antigens as an integral part of the humoral immune response to pathogenic microorganisms. Immunol Rev (2000) 176:154. doi:10.1034/j.1600-065X.2000.00607.x
23. Akira S, Takeda K, Kaisho T. Toll-like receptors: critical proteins linking innate and acquired immunity. Nat Immunol (2001) 2:675. doi:10.1038/90609
24. Heath WR, Carbone FR. Dendritic cell subsets in primary and secondary T cell responses at body surfaces. Nat Immunol (2009) 10:1237. doi:10.1038/ni.1822
25. Beutler B. Toll-like receptors: how they work and what they do. Curr Opin Hematol (2002) 9:2. doi:10.1097/00062752-200201000-00002
26. McHeyzer-Williams LJ, McHeyzer-Williams MG. Antigen-specific memory B cell development. Annu Rev Immunol (2005) 23:487. doi:10.1146/annurev.immunol.23.021704.115732
27. Schreiber RD, Old LJ, Smyth MJ. Cancer immunoediting: integrating immunity’s roles in cancer suppression and promotion. Science (2011) 331(6024):1565–70. doi:10.1126/science.1203486
28. Wang M, Zhao J, Zhang L, Wei FLian Y, Wu Y, Gong Z, et al. Role of tumor microenvironment in tumorigenesis. J Cancer (2017) 8(5):761–73. doi:10.7150/jca.17648
29. Balkwill FR, Capasso M, Hagemann T. The tumor microenvironment at a glance. J Cell Sci (2012) 125:5591–6. doi:10.1242/jcs.116392
30. Landskron G, De la Fuente M, Thuwajit P, Thuwajit C, Hermoso MA. Chronic inflammation and cytokines in the tumor microenvironment. J Immunol Res (2014) 2014:149185. doi:10.1155/2014/149185
31. Colotta F, Allavena P, Sica A, Garlanda C, Mantovani A. Cancer-related inflammation, the seventh hallmark of cancer: links to genetic instability. Carcinogenesis (2009) 30(7):1073–81. doi:10.1093/carcin/bgp127
32. Zamarin D, Jazaeri AA. Leveraging immunotherapy for the treatment of gynecologic cancers in the era of precision medicine. Gynecol Oncol (2016) 141:86–94. doi:10.1016/j.ygyno.2015.12.030
33. Bourla AB, Zamarin D. Immunotherapy: new strategies for the treatment of gynecologic malignancies. Oncology (Williston Park) (2016) 30(1):59–69.
34. Le DT, Durham JN, Smith KN, Wang H, Bartlett BR, Aulakh LK, et al. Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. Science (2017) 357(6349):409–13. doi:10.1126/science.aan6733
35. zur Hausen H. Papillomaviruses causing cancer: evasion from host-cell control in early events in carcinogenesis. J Natl Cancer Inst (2000) 92:690. doi:10.1093/jnci/92.9.690
36. Cory L, Chu C. ADXS-HPV: a therapeutic Listeria vaccination targeting cervical cancers expressing the HPV E7 antigen. Hum Vaccin Immunother (2014) 10:3190–5. doi:10.4161/hv.34378
37. Thornburg C, Boczkowski D, Gilboa E, Nair SK. Induction of cytotoxic T lymphocytes with dendritic cells transfected with human papillomavirus E6 and E7 RNA: implications for cervical cancer immunotherapy. J Immunother (2000) 23:412–8. doi:10.1097/00002371-200007000-00004
38. Ferrara A, Nonn M, Sehr P, Schreckenberger C, Pawlita M, Dürst M, et al. Dendritic cell-based tumor vaccine for cervical cancer II: results of a clinical pilot study in 15 individual patients. J Cancer Res Clin Oncol (2003) 129:521–30. doi:10.1007/s00432-003-0463-5
39. Santin AD, Bellone S, Palmieri M, Zanolini A, Ravaggi A, Siegel ER, et al. Human papillomavirus type 16 and 18 E7-pulsed dendritic cell vaccination of stage IB or IIA cervical cancer patients: a phase I escalating-dose trial. J Virol (2008) 82:1968–79. doi:10.1128/JVI.02343-07
40. Mezache L, Paniccia B, Nyinawabera A, Nuovo GJ. Enhanced expression of PD L1 in cervical intraepithelial neoplasia and cervical cancers. Mod Pathol (2015) 28:1594–602. doi:10.1038/modpathol.2015.108
41. Look KY, Blessing JA, Levenback C, Kohler M, Chafe W, Roman LD. A phase II trial of CPT-11 in recurrent squamous carcinoma of the cervix: a gynecologic Oncology group study. Gynecol Oncol (1998) 70:334. doi:10.1006/gyno.1998.5129
42. Stevanović S, Draper LM, Langhan MM, Campbell TE, Kwong ML, Wunderlich JR, et al. Complete regression of metastatic cervical cancer after treatment with human papillomavirus-targeted tumor-infiltrating T cells. J Clin Oncol (2015) 33:1543–50. doi:10.1200/JCO.2014.58.9093
43. Zhang L, Conejo-Garcia JR, Katsaros D, Gimotty PA, Massobrio M, Regnani G, et al. Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. New Engl J Med (2003) 348:203–13. doi:10.1056/NEJMoa020177
44. Sato E, Olson SH, Ahn J, Bundy B, Nishikawa H, Qian F, et al. Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer. Proc Natl Acad Sci U S A (2005) 102:18538–43. doi:10.1073/pnas.0509182102
45. Fujita K, Ikarashi H, Takakuwa K, Kodama S, Tokunaga A, Takahashi T, et al. Prolonged disease-free period in patients with advanced epithelial ovarian cancer after adoptive transfer of tumor-infiltrating lymphocytes. Clin Cancer Res (1995) 1:501–7.
46. Hodi FS, O’Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med (2010) 363:711–23. doi:10.1056/NEJMoa1003466
47. Hamid O, Robert C, Daud A, Hodi FS, Hwu WJ, Kefford R, et al. Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N Engl J Med (2013) 369:134–44. doi:10.1056/NEJMoa1305133
48. Hamanishi J, Mandai M, Ikeda T, Minami M, Kawaguchi A, Murayama T, et al. Safety and antitumor activity of anti-PD-1 antibody, nivolumab, in patients with platinum-resistant ovarian cancer. J Clin Oncol (2015) 33(34):4015–22. doi:10.1200/JCO.2015.62.3397
49. Disis ML, Patel MR, Pant S, Hamilton EP, Lockhart AC, Kelly K, et al. Avelumab (MSB0010718C; anti-PD-L1) in patients with recurrent/refractory ovarian cancer from the JAVELIN solid tumor phase Ib trial: safety and clinical activity. J Clin Oncol (2016) 34(15_suppl):5533. doi:10.1200/JCO.2016.34.15_suppl.5533
50. Varga A, Piha-Paul SA, Ott PA, Mehnert JM, Berton-Rigaud D, Johnson EA, et al. Antitumor activity and safety of pembrolizumab in patients (pts) with PD-L1 positive advanced ovarian cancer: Interim results from a phase Ib study. J Clin Oncol (2015) 33(15_suppl):5510. doi:10.1200/jco.2015.33.15_suppl.5510
52. Jerome L, Shiry L, Leyland-Jones B. Deregulation of the IGF axis in cancer: epidemiological evidence and potential therapeutic interventions. Endocr Relat Cancer (2003) 10:561–78. doi:10.1677/erc.0.0100561
53. Bruchim I, Werner H. Targeting IGF-1 signaling pathways in gynecologic malignancies. Expert Opin Ther Targets (2013) 17:307–20. doi:10.1517/14728222.2013.749863
54. Lemamy GJ, Sahla ME, Berthe ML, Roger P. Is the mannose-6-phosphate/IGF-2 receptor coded by a breast cancer suppressor gene? Adv Exp Med Biol (2008) 617:305–10. doi:10.1007/978-0-387-69080-3_28
55. Lodhia KA, Tienchaiananda P, Haluska P. Understanding the key to targeting the IGF axis in cancer: a biomarker assessment. Front Oncol (2015) 5:142. doi:10.3389/fonc.2015.00142
56. Werner H, Weinstein D, Bentov I. Similarities and differences between insulin and IGF-1: structures, receptors, and signalling pathways. Arch Physiol Biochem (2008) 114:17–22. doi:10.1080/13813450801900694
57. Frasca F, Pandini G, Scalia P, Sciacca L, Mineo R, Costantino A, et al. Insulin receptor isoform A, a newly recognized, high-affinity insulin-like growth factor II receptor in fetal and cancer cells. Mol Cell Biol (1999) 19:3278–88. doi:10.1128/MCB.19.5.3278
58. Belfiore A, Frasca F, Pandini G, Sciacca L, Vigneri R. Insulin receptor isoforms and insulin receptor/insulin-like growth factor receptor hybrids in physiology and disease. Endocrine Rev (2009) 30:586–623. doi:10.1210/er.2008-0047
59. Kahlert S, Nuedling S, van Eickels M, Vetter H, Meyer R, Grohe C. Estrogen receptor alpha rapidly activates the IGF-1 receptor pathway. J Biol Chem (2000) 275(24):18447–53. doi:10.1074/jbc.M910345199
60. Klotz DM, Hewitt SC, Ciana P, Raviscioni M, Lindzey JK, Foley J, et al. Requirement of estrogen receptor-α in insulin-like growth factor-1 (IGF-1)-induced uterine responses and in vivo evidence for IGF-1/estrogen receptor cross-talk. J Biol Chem (2002) 277:8531–7. doi:10.1074/jbc.M109592200
61. Merritt MA, Strickler HD, Einstein MH, Yang HP, Sherman ME, Wentzensen N, et al. Insulin/IGF and sex hormone axes in human endometrium and associations with endometrial cancer risk factors. Cancer Causes Control (2016) 27:737–48. doi:10.1007/s10552-016-0751-4
62. Renehan AG, Zwahlen M, Minder C, O’Dwyer ST, Shalet SM, Egger M. Insulin-like growth factor (IGF)-I, IGF binding protein-3, and cancer risk: systematic review and meta-regression analysis. Lancet (2004) 363:1346–53. doi:10.1016/S0140-6736(04)16044-3
63. Attias-Geva Z, Bentov I, Fishman A, Werner H, Bruchim I. Insulin-like growth factor-I receptor inhibition by specific tyrosine kinase inhibitor NVP-AEW541 in endometrioid and serous papillary endometrial cancer cell lines. Gynecol Oncol (2011) 121:383–9. doi:10.1016/j.ygyno.2011.01.008
64. Attias-Geva Z, Bentov I, Ludwig DL, Fishman A, Bruchim I, Werner H. Insulin-like growth factor-I receptor (IGF-IR) targeting with monoclonal antibody cixutumumab (IMC-A12) inhibits IGF-I action in endometrial cancer cells. Eur J Cancer (2011) 47:1717–26. doi:10.1016/j.ejca.2011.02.019
65. Mendivil A, Zhou C, Cantrell LA, Gehrig PA, Malloy KM, Blok LJ, et al. AMG 479, a novel IGF-1-R antibody, inhibits endometrial cancer cell proliferation through disruption of the PI3K/Akt and MAPK pathways. Reprod Sci (2011) 18:832–41. doi:10.1177/1933719111398501
66. Shen MR, Hsu YM, Hsu KF, Chen YF, Tang MJ, Chou CY. Insulin-like growth factor 1 is a potent stimulator of cervical cancer cell invasiveness and proliferation that is modulated by alphavbeta3 integrin signaling. Carcinogenesis (2006) 27:962–71. doi:10.1093/carcin/bgi336
67. Gotlieb WH, Bruchim I, Gu J, Shi Y, Camirand A, Blouin MJ, et al. Insulin-like growth factor receptor I targeting in epithelial ovarian cancer. Gynecol Oncol (2006) 100:389–96. doi:10.1016/j.ygyno.2005.09.048
68. Liefers-Visser JAL, Meijering RAM, Reyners AKL, van der Zee AGJ, de Jong S. IGF system targeted therapy: therapeutic opportunities for ovarian cancer. Cancer Treat Rev (2017) 60:90–9. doi:10.1016/j.ctrv.2017.08.012
69. Shao M, Hollar S, Chambliss D, Schmitt J, Emerson R, Chelladurai B, et al. Targeting the insulin growth factor and the vascular endothelial growth factor pathways in ovarian cancer. Mol Cancer Ther (2012) 11:1576–86. doi:10.1158/1535-7163.MCT-11-0961
70. Beauchamp MC, Knafo A, Yasmeen A, Carboni JM, Gottardis MM, Pollak MN, et al. BMS-536924 sensitizes human epithelial ovarian cancer cells to the PARP inhibitor, 3-aminobenzamide. Gynecol Oncol (2009) 115:193–8. doi:10.1016/j.ygyno.2009.07.009
71. Haluska P, Carboni JM, TenEyck C, Attar RM, Hou X, Yu C, et al. HER receptor signaling confers resistance to the insulin-like growth factor 1 receptor inhibitor, BMS-536924. Mol Cancer Ther (2008) 7:2589–98. doi:10.1158/1535-7163.MCT-08-0493
72. Hähnel PS, Thaler S, Antunes E, Huber C, Theobald M, Schuler M. Targeting AKT signaling sensitizes cancer to cellular immunotherapy. Cancer Res (2008) 68:3899–906. doi:10.1158/0008-5472.CAN-07-6286
73. Rothenberger NJ, Somasundaram A, Stabile LP. The role of the estrogen pathway in the tumor microenvironment. Int J Mol Sci (2018) 19:611. doi:10.3390/ijms19020611
74. Xuan NT, Hoang NH, Nhung VP, Duong NT, Ha NH, Hai NV. Regulation of dendritic cell function by insulin/IGF-1/PI3K/Akt signaling through klotho expression. J Recept Signal Transduct Res (2017) 37:297–303. doi:10.1080/10799893.2016.1247862
75. Bilbao D, Luciani L, Johannesson B, Piszczek A, Rosenthal N. Insulin-like growth factor-1 stimulates regulatory T cells and suppresses autoimmune disease. EMBO Mol Med (2014) 6:1423–35. doi:10.15252/emmm.201303376
76. Barrett JP, Minogue AM, Falvey A, Lynch MA. Involvement of IGF-1 and Akt in M1/M2 activation state in bone marrow-derived macrophages. Exp Cell Res (2015) 335:258–68. doi:10.1016/j.yexcr.2015.05.015
77. Shaw AK, Pickup MW, Chytil A, Aakre M, Owens P, Moses HL, et al. TGFbeta signaling in myeloid cells regulates mammary carcinoma cell invasion through fibroblast interactions. PLoS One (2015) 10:e0117908. doi:10.1371/journal.pone.0117908
78. Werner H, Karnieli E, Rauscher FJ, LeRoith D. Wild type and mutant p53 differentially regulate transcription of the insulin-like growth factor I receptor gene. Proc Natl Acad Sci U S A (1996) 93:8318–23. doi:10.1073/pnas.93.16.8318
79. Nahor I, Abramovitch S, Engeland K, Werner H. The p53-family members p63 and p73 inhibit insulin-like growth factor-I receptor gene expression in colon cancer cells. Growth Horm IGF Res (2005) 15:388–96. doi:10.1016/j.ghir.2005.07.005
80. Maor SB, Abramovitch S, Erdos MR, Brody LC, Werner H. BRCA1 suppresses insulin-like growth factor-I receptor promoter activity: potential interaction between BRCA1 and Sp1. Mol Genet Metab (2000) 69:130–6. doi:10.1006/mgme.1999.2958
81. Abramovitch S, Glaser T, Ouchi T, Werner H. BRCA1-Sp1 interactions in transcriptional regulation of the IGF-IR gene. FEBS Lett (2003) 541:149–54. doi:10.1016/S0014-5793(03)00315-6
82. Attias-Geva Z, Bentov I, Kidron D, Amichay K, Sarfstein R, Fishman A, et al. p53 Regulates insulin-like growth factor-I receptor gene expression in uterine serous carcinoma and predicts responsiveness to an insulin-like growth factor-I receptor-directed targeted therapy. Eur J Cancer (2012) 48:1570–80. doi:10.1016/j.ejca.2011.09.014
83. Bruchim I, Amichay K, Kidron D, Attias Z, Biron-Shental T, Drucker L, et al. BRCA1/2 germline mutations in Jewish patients with uterine serous carcinoma. Int J Gynecol Cancer (2010) 20:1148–53. doi:10.1111/IGC.0b013e3181ef622d
84. Werner H, Bruchim I. IGF-1 and BRCA1 signaling pathways in familial cancer. Lancet Oncol (2012) 13:537–44. doi:10.1016/S1470-2045(12)70362-5
85. Cohen-Sinai T, Cohen Z, Werner H, Berger R. Identification of BRCA1 as a potential biomarker for insulin-like growth factor-1 receptor targeted therapy in breast cancer. Front Endocrinol (2017) 8:148. doi:10.3389/fendo.2017.00148
86. Abboud SL, Bethel CR, Aron DC. Secretion of insulin like growth factor I and insulin like growth factor-binding proteins by murine bone marrow stromal cells. J Clin Invest (1991) 88:470–5. doi:10.1172/JCI115327
87. Stuart CA, Meehan RT, Neale LS, Cintron NM, Furlanetto RW. Insulin-like growth factor-I binds selectively to human peripheral blood monocytes and B-lymphocytes. J Clin Endocrinol Metab (1991) 72:1117–22. doi:10.1210/jcem-72-5-1117
88. Kooijman R, Willems M, De Haas CJ, Rijkers GT, Schuurmans AL, Van Buul-Offers SC, et al. Expression of type I insulin-like growth factor receptors on human peripheral blood mononuclear cells. Endocrinol (1992) 131:2244–50. doi:10.1210/endo.131.5.1425423
89. Badolato R, Bond HM, Valerio G, Petrella A, Morrone G, Waters MJ, et al. Differential expression of surface membrane growth hormone receptor on human peripheral blood lymphocytes detected by dual fluorochrome flow cytometry. J Clin Endocrinol Metab (1994) 79:984–90. doi:10.1210/jc.79.4.984
Keywords: immunotherapy, ovarian cancer, cervical cancer, endometrial cancer, gynecologic cancers, insulin-like growth factor 1 pathway, insulin-like growth factor 1 receptor, targeted therapy
Citation: Yahya MA, Sharon SM, Hantisteanu S, Hallak M and Bruchim I (2018) The Role of the Insulin-Like Growth Factor 1 Pathway in Immune Tumor Microenvironment and Its Clinical Ramifications in Gynecologic Malignancies. Front. Endocrinol. 9:297. doi: 10.3389/fendo.2018.00297
Received: 17 December 2017; Accepted: 17 May 2018;
Published: 05 June 2018
Edited by:
Teresa Wood, Rutgers University, The State University of New Jersey, United StatesReviewed by:
Roger Moorehead, University of Guelph, CanadaDragana Nikitovic, University of Crete, Greece
Marco Genua, Università Vita-Salute San Raffaele, Italy
Copyright: © 2018 Yahya, Sharon, Hantisteanu, Hallak and Bruchim. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Ilan Bruchim, ilan.bruchim@gmail.com
†These authors have contributed equally to this work.